TAKEDA PHARMACEUTICAL CO LTD's ticker is TAK and the CUSIP is 874060205. A total of 316 filers reported holding TAKEDA PHARMACEUTICAL CO LTD in Q3 2019. The put-call ratio across all filers is 1.05 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $20,231,000 | -8.8% | 1,111,580 | -10.6% | 0.06% | -20.0% |
| Q3 2020 | $22,189,000 | +20.1% | 1,243,782 | +20.7% | 0.08% | +10.3% |
| Q2 2020 | $18,476,000 | +62.2% | 1,030,442 | +37.3% | 0.07% | +36.0% |
| Q1 2020 | $11,393,000 | -43.1% | 750,544 | -26.1% | 0.05% | -30.6% |
| Q4 2019 | $20,031,000 | +40.8% | 1,015,231 | +22.7% | 0.07% | +28.6% |
| Q3 2019 | $14,229,000 | +34.4% | 827,273 | +38.3% | 0.06% | +30.2% |
| Q2 2019 | $10,584,000 | -41.1% | 597,964 | -32.2% | 0.04% | -44.9% |
| Q1 2019 | $17,975,000 | +346.8% | 882,411 | +268.9% | 0.08% | +290.0% |
| Q4 2018 | $4,023,000 | -41.7% | 239,187 | -17.6% | 0.02% | -79.4% |
| Q1 2014 | $6,895,000 | +6.6% | 290,284 | +3.0% | 0.10% | -3.0% |
| Q4 2013 | $6,470,000 | +16.6% | 281,882 | +19.9% | 0.10% | -6.5% |
| Q3 2013 | $5,551,000 | +20.3% | 235,055 | +14.8% | 0.11% | -2.7% |
| Q2 2013 | $4,615,000 | – | 204,669 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Glenview Capital Management | 16,104,222 | $294,063,000 | 4.98% |
| GMT CAPITAL CORP | 2,468,695 | $45,078,000 | 3.31% |
| MANAGED ASSET PORTFOLIOS, LLC | 1,065,756 | $19,461,000 | 3.13% |
| Blackcrane Capital, LLC | 14,571 | $1,723,000 | 2.72% |
| BFAM Partners (Cayman) Ltd | 328,690 | $6,002,000 | 2.36% |
| Paulson & Co. | 4,727,415 | $86,323,000 | 1.98% |
| Mondrian Investment Partners LTD | 3,510,404 | $59,677,000 | 1.28% |
| Lumbard & Kellner, LLC | 135,550 | $2,264,000 | 0.80% |
| DAVIDSON INVESTMENT ADVISORS | 500,203 | $9,134,000 | 0.78% |
| TFG Asset Management GP Ltd | 589,390 | $10,762,000 | 0.77% |